Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human OX40 / TNFRSF4 / CD134 Protein, Mouse IgG2a Fc Tag, low endotoxin, 100 µg  

Recombinant Human OX40 / TNFRSF4 / CD134 Protein, Mouse IgG2a Fc Tag, low endotoxin, 100 µg

Recombinant Human OX40 / TNFRSF4 / CD134 Protein, AA Leu 29 - Ala 216, expressed from human 293 cells (HEK293), Mouse IgG2a Fc Tag, low endotoxin

Synonym: Recombinant Human Protein, TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

More details

OX0-H5252-100

Availability: within 7 days

390,00 €

Background
Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

Source
Recombinant Human OX40, Mouse IgG2a Fc Tag, low endotoxin (OX0-H5252) is expressed from human 293 cells (HEK293). It contains AA Leu 29 - Ala 216 (Accession # P43489-1).
Predicted N-terminus: Leu 29

Molecular Characterization
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 47.1 kDa. The protein migrates as 58-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.1 EU per μg by the LAL method.
 
Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
 
Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Retracted: OX40-Fc Fusion Protein Alleviates PD-1-Fc-Aggravated Rheumatoid Arthritis by Inhibiting Inflammatory Response"
Methods In Medicine
Comput Math Methods Med (2023) 2023, 9893203
(2) "The OX40-TRAF6 axis promotes CTLA-4 degradation to augment antitumor CD8+ T-cell immunity"
Yu, Cui, Zhang et al
Cell Mol Immunol (2023)
(3) "The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer"
Choi, Lee, Jin et al
Breast Cancer Res (2023) 25 (1), 134
Showing 1-3 of 2078 papers.

The following products could also be interesting for you: